Ilya Pharma selected for Sparks IPO Academy Class of 2024/2025
Local-acting immunotherapies using bacterial vectors for drug delivery is gaining traction as the pipeline continues to deliver relevant clinical and preclinical data addressing multiple medical indications in diabetes, obesity to oncology and colitis
Uppsala, September 23, 2024: Ilya Pharma (the Company), a clinical stage immunotherapy company today announced that it has been selected for Sparks IPO Academy. The program has been predominantly designed for executives of Switzerland, with exceptions for selected European high-potential, fast-growing SMEs. This fast-track program prepares and equips respective companies for a potential IPO with information and network to facilitate listing and has been jointly developed with the leading capital market specialists in Switzerland, where multiple global pharma have significant presence.
Ilya Pharma CEO and Co-Founder Evelina Vågesjö adds: “We liked the concept of the program and are happy to be welcomed. There is no equivalent organized locally in the Nordics. This program spanning over 6 months fits well with the company’s next stage of growth as the investment sentiment returns to biotech and clinical stage biopharma, we are ready – one should always be ready.”
About Ilya Pharma - Ilya Pharma is a clinical stage biopharma company, developing novel drug candidates from its proprietary technology platform to clinical proof of concept in relevant patient groups with identified unmet medical needs. The lead drug candidate ILP100 is also known as emilomogene sigulactibac as recommended by the WHO. www.ilyapharma.se
For more information, please contact:
Evelina Vågesjö, CEO Tel: +46 (0) 70 636 64 94
Email: evelina.vagesjo@ilyapharma.se